PPIDT00254
Drug Information
| Name | Siltuximab |
|---|---|
| Sequence | EVQLVESGGKLLKPGGSLKLSCAASGFTFSSFAMSWFRQSPEKRLEWVAEISSGGSYTYYPDTVTGRFTISRDNAKNTLYLEMSSLRSEDTAMYYCARGLWGYYALDYWGQGTSVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB09036 |
| Type | biotech |
| Indication | Siltuximab is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. Siltuximab did not bind to virally produced IL-6 in a nonclinical study and was therefore not studied in patients with MCD who are HIV or HHV-8 positive. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection, powder, for solution | Intravenous |
100 mg/1
|
| Injection, powder, for solution | Intravenous |
400 mg/1
|
| Injection, powder, for solution | Intravenous; Parenteral |
100 MG
|
| Injection, powder, for solution | Intravenous; Parenteral |
400 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
100 mg/1
|
| Injection, powder, lyophilized, for solution | Intravenous |
400 mg/1
|
| Powder, for solution | Intravenous |
100 mg / vial
|
| Powder, for solution | Intravenous |
400 mg / vial
|
| Injection | Parenteral |
|
| Injection | Parenteral |
100 mg
|
| Injection, powder, for solution | Intravenous |
100 mg
|
| Injection | Parenteral |
400 mg
|
| Injection, powder, for solution | Intravenous |
400 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
100 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
400 mg
|
| Injection, solution, concentrate | Intravenous |
100 mg/1vial
|